Jan 11 2021 Read 1796 Times
Mass spectrometry is popular as an analytical tool in clinical laboratories and A Practical Guide to Implementing Clinical Mass Spectrometry Systems would be a valuable reference book for clinical labs. The aim of this publication is to provide practical guidance for laboratories on the implementation of mass spectrometry into a clinical service where there might be limited expertise in the technique. This guidance is the author’s personal recommendation based on over ten years’ experience of clinical mass spectrometry. Throughout the text, examples are given to illustrate issues that a clinical laboratory might encounter. While some examples relate to the field of immunosuppressive drug monitoring, the issues are common and relevant to any clinical application. The guidance provided is also applicable to instrumentation made by any manufacturer.
SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment
Dreamstime
Covid-19 lockdowns kept many scientists from their labs, and the interruption showed in the mid-2020 results of
Illumina, the supplier of technology for reading the genetic code.
Illumina’s business has now bounced back, its chief executive, Francis deSouza, told an online audience at J.P. Morgan’s annual health-care conference on Monday. He said that December 2020 quarter revenue was $950 million, or roughly flat with the quarter a year ago. Analysts had expected less than $880 million. Earnings for the December quarter were $1.20 a share, adjusted for certain one-time charges, compared with expectations for $1.05 a share.
Revenue should grow by 17% to 20% in 2021, deSouza said, and produce 2021 year earnings between $5.10 and $5.35 a share (also adjusting away expected noncash charges).